Search Within

Michael Morris

  1. "Biostatistics Service"
Formats
  1. Journal Article (55)
  2. Meeting Abstract (30)
  3. Review (2)
Groups
  1. Biostatistics Service (87)
  2. Department of Medicine (87)
  3. Epidemiology and Biostatistics (87)
  4. Genitourinary Oncology Service (87)
  5. Solid Tumor Oncology Division (87)
  6. Radiology, Department of (41)

More Groups

People
  1. Glenn Heller (54)
  2. Howard Scher (52)
  3. Steven Larson (29)
  4. Susan Slovin (22)
  5. Mithat Gonen (19)
  6. Dana Rathkopf (15)

More People

Years
  1. 2025 (3)
  2. 2024 (11)
  3. 2023 (7)
  4. 2022 (9)
  5. 2021 (7)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Clinical Cancer Research (9)
  3. Journal of Nuclear Medicine (6)
  4. Cancer (3)
  5. Clinical Genitourinary Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (36)
  2. American Association for Cancer Research (10)
  3. Society of Nuclear Medicine (6)
  4. Elsevier Science, Inc. (5)
  5. Oxford University Press (5)
  6. Elsevier BV (4)

More Publishers

Results (87)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
    Journal Article

    Fleming, M. T.; Morris, M. J.; Heller, G.; Scher, H. I.
    Nature Clinical Practice Oncology (2006)

    Fulltext@MSK | Save
  • Rapid androgen cycling as treatment for patients with prostate cancer
    Journal Article

    Feltquate, D.; Nordquist, L.; Eicher, C.; Morris, M.; Smaletz, O.; Slovin, S.; Curley, T.; Wilton, A.; Fleisher, M.; Heller, G.; more...
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Journal Article

    Scher, H. I.; Morris, M. J.; Kelly, W. K.; Schwartz, L. H.; Heller, G.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Journal Article

    Morris, M. J.; Akhurst, T.; Larson, S. M.; Ditullio, M.; Chu, E.; Siedlecki, K.; Verbel, D.; Heller, G.; Kelly, W. K.; Slovin, S.; more...
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen
    Journal Article

    Beekman, K.; Morris, M.; Slovin, S.; Heller, G.; Wilton, A.; Bianco, F.; Scardino, P. T.; Scher, H. I.
    Urology (2005)

    Fulltext@MSK | Save
  • Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): The MEN's Cycle
    Meeting Abstract

    Nordquist, L.; Sauter, N.; Morris, M.; Smaletz, O.; Konopelski, K.; Delacruz, A.; Heller, G.; Scher, H. I.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group
    Journal Article

    Scher, H. I.; Eisenberger, M.; D'Amico, A. V.; Halabi, S.; Small, E. J.; Morris, M.; Kattan, M. W.; Roach, M.; Kantoff, P.; Pienta, K. J.; more...
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save